<DOC>
	<DOCNO>NCT01430273</DOCNO>
	<brief_summary>Main Objective : The purpose study demonstrate whether correlation perioperative blood loss degree platelet inhibition assess point care assay patient undergo hip knee arthroplasty treat antiplatelet mono/bi-therapy</brief_summary>
	<brief_title>Assessment Blood Loss With Point Of Care Device</brief_title>
	<detailed_description>Type study : Prospective , non-interventional , multicenter registry Principal Investigator : Collet Jean-Philippe Rational : Discontinuation antiplatelet therapy patient establish coronary artery disease ( CAD ) become increasingly important concern give risk recurrent arterial event . Exaggerated concern increase procedure-related bleeding remain major factor premature discontinuation APT . Interruption modality impact perioperative bleeding never prospectively evaluate accepted maximum duration interruption exceed 5 day Clopidogrel/Ticagrelor 7 day Prasugrel give fact remain antiplatelet effect APT observe less 50 % patient 3 day interruption . Resuming APT operation never study remains complex situation anticoagulation often prescribed prevent deep vein thrombosis increase perioperative bleeding . Hypotheses : ( ) volume perioperative blood loss correlate degree platelet inhibition . ( ii ) Clopidogrel metabolizer status define genetic profile also correlate perioperative blood loss . ( iii ) Resuming antiplatelet therapy perioperative period associate significant recovery antiplatelet effect . Primary endpoint : Perioperative ( day 1-day 5 ) blood loss mL assess NADLER &amp; Mercurial formula* PRU** ( patient Clopidogrel/ARU*** measure use VerifyNow®P2Y12 aspirin assay baseline . Secondary objective : ( ) evaluate correlation clopidogrel genetic metabolizer status**** perioperative blood loss . To evaluate antiplatelet pharmacodynamic response discharge accord metabolizer status . Definition*Blood loss mL Red Blood Cell ( RBC ) = Compensated RBC Volume ( 1 Pack=150mL ) + Non Compensated RBC Vol . ( Total Blood Loss : Ht D-1-Ht D+5 ) . *PRU=Platelet Reaction Unit . It specific measure on-clopidogrel platelet reactivity . Cut-off value define high-on clopidogrel platelet reactivity 230 . **ARU=Aspirin Reaction Unit . It specific measure on-aspirin platelet reactivity . Cutoff value identify high on-aspirin platelet reactivity 550 . ***Clopidogrel Metabolizer Phenotype define accord carriage loss/gain-of function allele 2C19*2-*8/*17 follow : SM slow metabolizer : ( *2-*8/*2-*8 ) ; Ultrafast Metabolizer ( FM ) : ( *17/*17 ) ; Normal/intermediate ( M ) : ( wt/wt , wt/*17 , *2-*8/*17 *2-*8/wt ) Number subject : 200 patient Study duration : Two year . Study duration per subject : length hospital stay maximum duration 30 day .</detailed_description>
	<criteria>≥18 year Patient antiplatelet monotherapy ( aspirin clopidogrel ) dual therapy ( aspirin + clopidogrel / prasugrel / ticagrelor ) context secondary prevention : acute coronary syndrome / intracoronary stenting Planned urgent hip ( gamma nail , total prosthesis DHS ) knee arthroplasty Informed consent participant Patient receive social security scheme entitle Polytrauma Anemia &lt; 9g/dL Indication oral anticoagulation Pelvic fracture justify complex surgery Ongoing recent major bleed recent major surgery ( &lt; 3 week ) Liver failure Thrombopenia &lt; 80 000/µl Lack health insurance Mental disability Participation research protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Antiplatelet therapy</keyword>
	<keyword>Surgery</keyword>
	<keyword>Bleeding</keyword>
	<keyword>Platelet aggregation</keyword>
</DOC>